First-in-class drug 'effective' in hypertrophic cardiomyopathy
The results show the benefit of disease-targeted therapy, researchers say
AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.
Mavacamten, a first-in-class cardiac myosin inhibitor, improves a range of outcomes in patients with obstructive hypertrophic cardiomyopathy, trial results show.
Results of the EXPLORER-HCM trial, presented at the European Society of Cardiology’s virtual congress (ESC 2020) this week compared outcomes of 123 people randomised to mavacamten (starting at 5mg) with 128